A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Reinhard Dummer(University Hospital of Zurich), Antoni Ribas(University of California, Los Angeles), Adil Daud(University of California, San Francisco), Jacob Schachter, Omid Hamid(Cedars-Sinai Medical Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Anna C. Pavlick(Cornell University), Lee D. Cranmer(University of Washington), Steven O’Day(Saint John's Health Center), Nicole Xiaoyun Li(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joy Lis(Merck & Co., Inc., Rahway, NJ, USA (United States)), F. Stephen Hodi(Harvard University), Christian U. Blank(The Netherlands Cancer Institute), April K.S. Salama(Duke University), Caroline Robert(Institut Gustave Roussy), Wei Zhou(Nanchang University), René González(University of Miami), Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 94
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k